Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Brian Curran Healy, Ph.D.

Co-Author

This page shows the publications co-authored by Brian Healy and Tanuja Chitnis.
Connection Strength

13.691
  1. Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. Mult Scler Int. 2013; 2013:189624.
    View in: PubMed
    Score: 0.564
  2. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. J Neurol Sci. 2011 Apr 15; 303(1-2):109-13.
    View in: PubMed
    Score: 0.486
  3. A method for evaluating treatment switching criteria in multiple sclerosis. Mult Scler. 2010 Dec; 16(12):1483-9.
    View in: PubMed
    Score: 0.473
  4. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler. 2009 May; 15(5):627-31.
    View in: PubMed
    Score: 0.428
  5. The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Apr-Jun; 7(2):20552173211007523.
    View in: PubMed
    Score: 0.249
  6. Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Apr-Jun; 7(2):2055217321999070.
    View in: PubMed
    Score: 0.247
  7. Obesity is associated with the Optic Neuritis severity in Male patients with Multiple Sclerosis. Mult Scler Relat Disord. 2021 Mar 21; 51:102910.
    View in: PubMed
    Score: 0.246
  8. Serum neurofilament levels and patient-reported outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2021 03; 8(3):631-638.
    View in: PubMed
    Score: 0.243
  9. MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. J Neuroimaging. 2021 03; 31(2):388-393.
    View in: PubMed
    Score: 0.243
  10. Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety. J Psychosom Res. 2020 11; 138:110252.
    View in: PubMed
    Score: 0.237
  11. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. Ann Clin Transl Neurol. 2020 06; 7(6):945-955.
    View in: PubMed
    Score: 0.232
  12. Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis. Mult Scler. 2021 04; 27(4):593-602.
    View in: PubMed
    Score: 0.230
  13. Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. Mult Scler Relat Disord. 2020 May; 40:101944.
    View in: PubMed
    Score: 0.227
  14. Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. NPJ Digit Med. 2019; 2:123.
    View in: PubMed
    Score: 0.225
  15. Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. NPJ Digit Med. 2019 Dec 11; 2(1):123.
    View in: PubMed
    Score: 0.225
  16. Adipokines are associated with pediatric multiple sclerosis risk and course. Mult Scler Relat Disord. 2019 Nov; 36:101384.
    View in: PubMed
    Score: 0.221
  17. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Mult Scler Relat Disord. 2019 Oct; 35:119-127.
    View in: PubMed
    Score: 0.219
  18. Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients. Mult Scler J Exp Transl Clin. 2019 Jan-Mar; 5(1):2055217319828400.
    View in: PubMed
    Score: 0.213
  19. The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. BMC Neurol. 2019 Feb 12; 19(1):23.
    View in: PubMed
    Score: 0.213
  20. Time between expanded disability status scale (EDSS) scores. Mult Scler Relat Disord. 2019 May; 30:98-103.
    View in: PubMed
    Score: 0.212
  21. Food allergies are associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019 06; 90(6):629-635.
    View in: PubMed
    Score: 0.210
  22. Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis. Mult Scler. 2019 11; 25(13):1791-1799.
    View in: PubMed
    Score: 0.209
  23. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2018 Dec; 5(12):1478-1491.
    View in: PubMed
    Score: 0.208
  24. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. J Neurol Sci. 2018 11 15; 394:127-131.
    View in: PubMed
    Score: 0.207
  25. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. Mult Scler Relat Disord. 2018 Feb; 20:51-57.
    View in: PubMed
    Score: 0.196
  26. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2017 Nov; 18:196-201.
    View in: PubMed
    Score: 0.194
  27. The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. Mult Scler Relat Disord. 2017 Oct; 17:47-53.
    View in: PubMed
    Score: 0.190
  28. Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients. Mult Scler. 2018 07; 24(8):1126-1130.
    View in: PubMed
    Score: 0.189
  29. Exploration of machine learning techniques in predicting multiple sclerosis disease course. PLoS One. 2017; 12(4):e0174866.
    View in: PubMed
    Score: 0.187
  30. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. J Neuroimaging. 2017 09; 27(5):481-485.
    View in: PubMed
    Score: 0.186
  31. Risk attitudes and risk perceptions in individuals with multiple sclerosis. Mult Scler J Exp Transl Clin. 2016 Jan-Dec; 2:2055217316665406.
    View in: PubMed
    Score: 0.179
  32. Longitudinal BMI trajectories in multiple sclerosis: Sex differences in association with disease severity. Mult Scler Relat Disord. 2016 Jul; 8:136-40.
    View in: PubMed
    Score: 0.176
  33. Effect of vitamin D on MS activity by disease-modifying therapy class. Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e167.
    View in: PubMed
    Score: 0.169
  34. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler. 2016 06; 22(7):935-43.
    View in: PubMed
    Score: 0.169
  35. Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure. Mult Scler Relat Disord. 2015 Nov; 4(6):598-606.
    View in: PubMed
    Score: 0.168
  36. The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS. Neurology. 2015 Oct 06; 85(14):1209-13.
    View in: PubMed
    Score: 0.168
  37. Removing confounding factors via constraint-based clustering: An application to finding homogeneous groups of multiple sclerosis patients. Artif Intell Med. 2015 Oct; 65(2):79-88.
    View in: PubMed
    Score: 0.166
  38. Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models. Neuroimage Clin. 2015; 8:606-10.
    View in: PubMed
    Score: 0.165
  39. Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis. Neuroimage. 2015 Oct 01; 119:81-8.
    View in: PubMed
    Score: 0.165
  40. Clinical and MRI phenotype of children with MOG antibodies. Mult Scler. 2016 Feb; 22(2):174-84.
    View in: PubMed
    Score: 0.165
  41. Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis. Mult Scler. 2016 Mar; 22(3):354-61.
    View in: PubMed
    Score: 0.165
  42. Joint assessment of dependent discrete disease state processes. Stat Methods Med Res. 2017 Jun; 26(3):1182-1198.
    View in: PubMed
    Score: 0.161
  43. Progression rates and sample size estimates for PPMS based on the CLIMB study population. Mult Scler. 2015 Feb; 21(2):180-8.
    View in: PubMed
    Score: 0.155
  44. Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. Neurology. 2014 Jun 17; 82(24):2173-9.
    View in: PubMed
    Score: 0.153
  45. Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler. 2014 Oct; 20(12):1584-92.
    View in: PubMed
    Score: 0.152
  46. Treatment satisfaction in multiple sclerosis. Int J MS Care. 2014; 16(2):68-75.
    View in: PubMed
    Score: 0.149
  47. Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurol. 2013 Nov 13; 13:173.
    View in: PubMed
    Score: 0.148
  48. Increased leptin and A-FABP levels in relapsing and progressive forms of MS. BMC Neurol. 2013 Nov 11; 13:172.
    View in: PubMed
    Score: 0.148
  49. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy. Mult Scler. 2014 May; 20(6):757-60.
    View in: PubMed
    Score: 0.148
  50. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord. 2014 Mar; 3(2):186-93.
    View in: PubMed
    Score: 0.144
  51. No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. BMC Neurol. 2013 Jul 03; 13:73.
    View in: PubMed
    Score: 0.144
  52. Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. Value Health. 2012 Dec; 15(8):1029-35.
    View in: PubMed
    Score: 0.137
  53. Diffusion tensor analysis of pediatric multiple sclerosis and clinically isolated syndromes. AJNR Am J Neuroradiol. 2013 Feb; 34(2):417-23.
    View in: PubMed
    Score: 0.135
  54. Effect of gender on late-onset multiple sclerosis. Mult Scler. 2012 Oct; 18(10):1472-9.
    View in: PubMed
    Score: 0.131
  55. The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis. Qual Life Res. 2012 Dec; 21(10):1677-84.
    View in: PubMed
    Score: 0.130
  56. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology. 2011 Jun 07; 76(23):1996-2001.
    View in: PubMed
    Score: 0.125
  57. Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies. J Neurol. 2011 Oct; 258(10):1812-9.
    View in: PubMed
    Score: 0.123
  58. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010 Aug 17; 75(7):634-40.
    View in: PubMed
    Score: 0.118
  59. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul; 66(7):858-64.
    View in: PubMed
    Score: 0.109
  60. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009 Jan; 66(1):54-9.
    View in: PubMed
    Score: 0.105
  61. Gut Microbiome in Progressive Multiple Sclerosis. Ann Neurol. 2021 Jun; 89(6):1195-1211.
    View in: PubMed
    Score: 0.062
  62. Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis. Mult Scler Int. 2020; 2020:5471987.
    View in: PubMed
    Score: 0.060
  63. MRI activity in MS and completed pregnancy: Data from a tertiary academic center. Neurol Neuroimmunol Neuroinflamm. 2020 11 05; 7(6).
    View in: PubMed
    Score: 0.059
  64. Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. Neurol Neuroimmunol Neuroinflamm. 2020 11; 7(6).
    View in: PubMed
    Score: 0.059
  65. History of fatigue in multiple sclerosis is associated with grey matter atrophy. Sci Rep. 2019 10 14; 9(1):14781.
    View in: PubMed
    Score: 0.056
  66. Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression. Mult Scler. 2020 11; 26(13):1708-1718.
    View in: PubMed
    Score: 0.055
  67. The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. J Neurol Sci. 2019 Aug 15; 403:38-43.
    View in: PubMed
    Score: 0.054
  68. Identification of MS-specific serum miRNAs in an international multicenter study. Neurol Neuroimmunol Neuroinflamm. 2018 Sep; 5(5):e491.
    View in: PubMed
    Score: 0.051
  69. Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. eNeurologicalSci. 2018 Sep; 12:42-46.
    View in: PubMed
    Score: 0.051
  70. Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis. J Neurol Sci. 2018 09 15; 392:94-99.
    View in: PubMed
    Score: 0.051
  71. Short Report: A Pilot Study of a Group Positive Psychology Intervention for Patients with Multiple Sclerosis. Int J MS Care. 2018 May-Jun; 20(3):136-141.
    View in: PubMed
    Score: 0.050
  72. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve. 2018 Aug; 58(2):261-269.
    View in: PubMed
    Score: 0.050
  73. Evaluating the Association between Enlarged Perivascular Spaces and Disease Worsening in Multiple Sclerosis. J Neuroimaging. 2018 05; 28(3):273-277.
    View in: PubMed
    Score: 0.049
  74. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. J Neurol Sci. 2017 Dec 15; 383:221-229.
    View in: PubMed
    Score: 0.048
  75. Depression and fatigue in patients with multiple sclerosis. J Neurol Sci. 2017 Sep 15; 380:236-241.
    View in: PubMed
    Score: 0.048
  76. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. JAMA Neurol. 2017 03 01; 74(3):275-285.
    View in: PubMed
    Score: 0.046
  77. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. Int J Neurosci. 2017 Nov; 127(11):971-980.
    View in: PubMed
    Score: 0.046
  78. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016 Oct; 3(5):e267.
    View in: PubMed
    Score: 0.045
  79. Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients. Mult Scler. 2016 12; 22(14):1841-1849.
    View in: PubMed
    Score: 0.043
  80. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. J Neuroimaging. 2016 Mar-Apr; 26(2):184-7.
    View in: PubMed
    Score: 0.042
  81. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. J Neurol. 2015 Nov; 262(11):2425-32.
    View in: PubMed
    Score: 0.042
  82. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015 Feb; 72(2):152-8.
    View in: PubMed
    Score: 0.040
  83. Patients report worse MS symptoms after menopause: findings from an online cohort. Mult Scler Relat Disord. 2015 Jan; 4(1):18-24.
    View in: PubMed
    Score: 0.040
  84. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Neuroreport. 2014 Oct 01; 25(14):1156-61.
    View in: PubMed
    Score: 0.039
  85. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Mult Scler. 2014 Sep; 20(10):1381-90.
    View in: PubMed
    Score: 0.038
  86. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013 Nov 26; 81(22):1891-9.
    View in: PubMed
    Score: 0.037
  87. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler. 2014 Apr; 20(4):438-44.
    View in: PubMed
    Score: 0.036
  88. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol. 2013 Jun; 73(6):729-40.
    View in: PubMed
    Score: 0.036
  89. Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One. 2013; 8(3):e59707.
    View in: PubMed
    Score: 0.035
  90. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci. 2012 Apr 15; 315(1-2):49-54.
    View in: PubMed
    Score: 0.032
  91. Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry. 2012 Jan; 83(1):38-43.
    View in: PubMed
    Score: 0.031
  92. One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011 Oct; 82(10):1125-31.
    View in: PubMed
    Score: 0.031
  93. Patient reported outcomes in benign multiple sclerosis. Mult Scler. 2011 Jul; 17(7):876-84.
    View in: PubMed
    Score: 0.031
  94. Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol. 2011 Apr; 233(1-2):168-74.
    View in: PubMed
    Score: 0.030
  95. Tract-based analysis of callosal, projection, and association pathways in pediatric patients with multiple sclerosis: a preliminary study. AJNR Am J Neuroradiol. 2010 Jan; 31(1):121-8.
    View in: PubMed
    Score: 0.028
  96. Regional white matter atrophy--based classification of multiple sclerosis in cross-sectional and longitudinal data. AJNR Am J Neuroradiol. 2009 Oct; 30(9):1731-9.
    View in: PubMed
    Score: 0.028
  97. Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study. J Neurol Sci. 2009 Apr 15; 279(1-2):99-105.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.